Send the following on WhatsApp
Continue to Chat20 年來首個 DLBCL 一線療法獲 FDA 核准,Polivy 組合治療死亡風險降 27% https://geneonline.news/polivy-dlbcl-first-line-approval/
20 年來首個 DLBCL 一線療法獲 FDA 核准,Polivy 組合治療死亡風險降 27% https://geneonline.news/polivy-dlbcl-first-line-approval/